To determine the role of CYP450 copy number variation (CNV) beyond CYP2D6, 11 CYP450 genes were interrogated by multiplex ligation-dependent probe amplification and quantitative PCR in 542 African-American, Asian, Caucasian, Hispanic and Ashkenazi Jewish individuals. The CYP2A6, CYP2B6 and CYP2E1 combined deletion/duplication allele frequencies ranged from 2 to 10% in these populations. High-resolution microarray-based comparative genomic hybridization (aCGH) localized CYP2A6, CYP2B6 and CYP2E1 breakpoints to directly oriented low-copy repeats. Sequencing localized the CYP2B6 breakpoint to a 529-bp intron 4 region with high homology to CYP2B7P1, resulting in the CYP2B6*29 partial deletion allele and the reciprocal, and novel, CYP2B6/2B7P1 duplicated fusion allele (CYP2B6*30). Together, these data identified novel CYP450 CNV alleles (CYP2B6*30 and CYP2E1*1Cx2) and indicate that common CYP450 CNV formation is likely mediated by non-allelic homologous recombination resulting in both full gene and gene-fusion copy number imbalances. Detection of these CNVs should be considered when interrogating these genes for pharmacogenetic drug selection and dosing.
INTRODUCTION
The significance of structural variation in human disease and phenotypic diversity has increasingly become recognized [1] [2] [3] and several studies have generated catalogs of copy number variants (CNVs) in the human genome to facilitate a better understanding of their functional relevance. [4] [5] [6] [7] [8] [9] It is estimated that B12% of the human genome contains CNVs, which range in size from o1 kb to several megabases. 10 A number of mechanisms of CNV formation have been proposed including non-allelic homologous recombination (NAHR), non-homologous end joining, fork stalling and template switching, and microhomology-mediated break-induced replication. 11, 12 Like single-nucleotide polymorphisms, CNVs not only influence disease susceptibility but also interindividual differences in drug response, as several important pharmacogenetic genes are known to have variable copy number (for example, CYP2D6, GSTT1, GSTM1, SULT1A1 and UGT2B17).
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The polymorphic cytochrome-P450 (CYP450) system is a superfamily of 56 functional genes (and over 50 highly homologous pseudogenes) that are principally involved in drug metabolism and bioactivation. 16 Inherited genetic variation among the CYP450 genes contributes to disease susceptibility and interindividual differences in drug response. While singlenucleotide polymorphisms represent an important form of CYP450 variation that can influence enzyme activity, CNVs also can affect CYP450 activity by altering gene expression. 17, 18 However, most studies on CYP450 CNVs have focused on CYP2D6 [18] [19] [20] [21] and to a lesser extent on CYP2A6, 22, 23 with limited CNV population data on other CYP450 family members. This is primarily because CNV detection is challenging for some CYP450 genes due to the presence of homologous gene family members, pseudogenes and complex rearrangements including chimeras and gene conversions. For example, CYP2D6 CNV characterization and metabolizer phenotype assignment is convoluted by the presence of CYP2D6/2D7P1 hybrid alleles 21 and the fact that not all duplication alleles encode functional enzymes (for example, increased function CYP2D6*2xN, reduced function CYP2D6*10xN and non-functional CYP2D6*4xN). 18, [24] [25] [26] Thus, this study aimed to determine the prevalence of CNVs in CYP450 genes other than CYP2D6 in a large multi-ethnic cohort of healthy, unrelated African-American, Asian, Caucasian, Hispanic and Ashkenazi Jewish (AJ) individuals. Copy number was determined for 11 CYP450 genes by multiplex ligation-dependent probe amplification (MLPA) and validated by quantitative PCR (qPCR) copy number assays. Additionally, a subset of samples were subjected to high-resolution microarray-based comparative genomic hybridization (aCGH) to accurately map the size of identified CNVs and localize breakpoint intervals. In addition to revealing the diverse frequency profiles of CYP450 CNVs across multi-ethnic populations, these studies also identified two novel CYP450 alleles, CYP2B6*30 and CYP2E1*1Cx2. Moreover, the frequency data offer insight into the adaptive evolution of CYP450 CNVs and the breakpoint analyses provide insight into their mechanism of formation.
MATERIALS AND METHODS

Study population
Peripheral blood samples from healthy donors who indicated their racial/ ethnic background and gave informed consent for the use of their DNA for research were obtained from the New York Blood Center with Institutional 1 Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, NY, USA and Review Board (IRB) approval. [27] [28] [29] In addition, blood samples were obtained with informed consent from unrelated, healthy 100% AJ individuals from the greater New York metropolitan area as previously described. 28, [30] [31] [32] All personal identifiers were removed, and the isolated DNA samples were tested anonymously. Genomic DNA was isolated using the Puregene DNA Purification kit (Qiagen, Valencia, CA, USA) according to manufacturer's instructions. Individuals from five different populations were subjected to CYP450 CNV testing: African-American (n ¼ 105), Asian (n ¼ 102), Caucasian (n ¼ 103), Hispanic (n ¼ 109) and AJ (n ¼ 123).
Multiplex ligation-dependent probe amplification MLPA was performed using the recently developed Cytochrome P-450 MLPA kit (P128-B1; MRC-Holland, Amsterdam, The Netherlands) as per manufacturer's instructions. This probe mix included 2-5 MLPA probes each for CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4 and CYP3A5. In brief, all DNA samples were diluted to 200 ng with tris-EDTA buffer and denatured in a thermalcycler for 5 min at 98 1C. After cooling to 25 1C, probe mix and MLPA buffer were added to each sample, mixed and incubated for 1 min at 95 1C followed by 16 h hybridization at 60 1C. The ligation reaction was performed at 54 1C by adding 32 ml of Ligase-65 mix to each tube followed by heating for 5 min at 98 1C. PCR buffer, water and MLPA ligation reactions were mixed in new tubes and maintained in a thermalcycler at 60 1C, while polymerase mix was added to each tube. Exon-specific probes with universal-tagged primers underwent PCR that consisted of 35 amplification cycles (95 1C for 30 s, 60 1C for 30 s and 72 1C for 60 s), followed by a 20-min incubation at 72 1C. Amplified products were separated by capillary gel electrophoresis and analyzed using GeneMarker v1.90 software (SoftGenetics, State College, PA, USA). After quality control and data normalization to 12 autosome reference probes (Supplementary Table S1 ), copy number was determined according to the following peak ratio ranges: one copy 40.25 and o0.75; two copies 40.75 and o1.25; three copies 41.25 and o1.7; four copies 41.7 and o2.0. The copy numbers of CYP2A6, CYP2B6 and CYP2E1 alleles were determined using the average values of interrogated intragenic probes (four, three and three probes, respectively).
Copy number analyses using qPCR
The copy number of selected genes was interrogated using commercially available TaqMan real-time qPCR Copy Number Assays (Applied Biosystems, Carlsbad, CA, USA) as per manufacturer's instructions. In brief, FAMlabeled CYP2A6, CYP2B6 and CYP2E1 TaqMan minor groove binding probes and unlabeled PCR primers (Supplementary Table S2) were individually run in a duplex qPCR with a VIC-labeled RNase P TaqMan Copy Number Reference Assay (catalog number: 4403326; Applied Biosystems). Quadruplicate experiments were each performed in 10 ml reactions containing B10 ng of DNA, 1 Â TaqMan Genotyping Master mix, 0.5 ml each of TaqMan Copy Number and Reference Assays in 384-well plates. Covered plates were run in a 7900HT Fast Real-Time PCR System (Applied Biosystems) and the amplification consisted of a denaturation step at 95 1C for 10 min followed by 40 amplification cycles (95 1C for 15 s and 60 1C for 60 s). Data were captured using absolute quantitation with a manual C T threshold and autobaseline, followed by analysis using CopyCaller v1.0 Software (Applied Biosystems) where the number of copies of target sequence was determined by relative quantitation with the comparative C T (DDC T ) method. This method measures the C T difference (DC T ) between target and reference sequences, and then compares the DC T values of test samples to a calibrator sample known to have two copies of the target sequence. The copy number of the target was calculated to be two times the relative quantity.
Microarray-based comparative genomic hybridization
To map the breakpoint regions of identified CNVs, a custom oligonucleotide microarray was designed using eArray (https://earray.chem.agilent. com/earray/; Agilent Technologies, Santa Clara, CA, USA) that included unique high-density catalog probes corresponding to the February 2009 human genome assembly, NCBI Build 37 (hg19). Specifically, CYP2A6, CYP2B6 and CYP2E1 were assessed by interrogating the following chromosome nucleotide intervals: chr19:41 255 363-41 551 068 (1224 probes; B242 bp resolution) and chr10:134 507 520-135 534 747 (7995 probes; B128 bp resolution). In addition, a whole-genome backbone of 3000 interspersed probes was included on the array with 300 wholegenome probes replicated five times to provide a feature extraction quality control measure.
All aCGH experiments were performed according to manufacturer's instructions and as previously described. [33] [34] In brief, B1 mg each of experimental and reference DNAs were double digested with AluI and RsaI restriction endonucleases (Promega, Madison, WI, USA) and fluorescently labeled with Cyanine 5-dCTP (Cy-5; experimental) and Cyanine 3-dCTP (Cy-3; reference) using the Genomic DNA Labeling kit (Agilent Technologies). Labeled experimental and reference DNAs were purified, combined, denatured, pre-annealed with Cot-1 DNA (Invitrogen, Carlsbad, CA, USA) and blocking reagent (Agilent Technologies), and hybridized to arrays in a rotating oven (20 r.p.m.) at 65 1C for 24 h. After hybridization and recommended washes, the arrays were scanned at 5 mm resolution with a G2505C Agilent Microarray Scanner. Images were processed and the data analyzed with CytoGenomics 1.5 software (both from Agilent Technologies). All array data passed the recommended quality control metrics. Breakpoints were defined as interprobe regions with surrounding average log 2 ratios that indicated a change in copy number from two to one or three copies.
CYP2B6 and CYP2E1 sequence analyses
The breakpoint regions (B3 kb) of the CYP2B6/2B7P1 fusion alleles (CYP2B6*29 and *30) were assessed by breakpoint-spanning PCR using overlapping primers (Supplementary Table S3 ) and the SequalPrep Long PCR Kit (Invitrogen). In addition, long-range PCR was performed to generate CYP2B6 and CYP2B7P1 gene fusion-specific amplicons of 18 and 11 kb spanning exons 1-5 and exons 4-9, respectively, which were used as templates for exon and exon-intron junction sequencing using primers listed in Supplementary Table S3 . DNA samples from four controls with two copies of CYP2B6 by MLPA and qPCR were included as negative controls. Long-range PCRs were performed in 20 ml containing B100 ng of DNA, SequalPrep 1 Â PCR buffer, 0.4 ml DMSO, SequalPrep 1 Â Enhancer A, 0.5 mM of forward and reverse primers (Supplementary Table S3 Additionally, for selected subjects, all CYP2B6 exons and exon/intron boundaries were individually amplified and sequenced using exon primers listed in Supplementary  Table S3 .
For subjects harboring a CYP2E1 duplication, long-range PCR was performed to generate a CYP2E1-specific amplicon of B3 kb spanning the promoter region and exon 1 using conditions detailed above and primers listed in Supplementary Table S4 . Exons 2-9 of CYP2E1 were also amplified and directly sequenced using primers listed in Supplementary Table S4 .
All amplicons were digested with 3.0 units of shrimp alkaline phosphatase and 2.0 units of Exonuclease I (both from USB Corporation, Cleveland, OH, USA) and bidirectionally sequenced using amplification and/or sequencing primers. Sequencing was performed on an ABI 3700 Sequencer (Applied Biosystems) and sequence chromatograms were analyzed using Mutation Surveyor software v3.30 (SoftGenetics).
RESULTS
CYP450 copy number profiling CNVs were interrogated with an MLPA panel of 11 CYP450 genes (CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4 and CYP3A5) among 542 healthy, unrelated African-American, Asian, Caucasian, Hispanic and AJ individuals. In addition to CYP2D6 (data not shown), CNVs were detected in CYP2A6, CYP2B6 and CYP2E1. Representative MLPA data from samples with variable CYP450 copy number are shown in Table 1 and Supplementary Table S1 , and the identified CYP2A6, CYP2B6 and CYP2E1 allele frequencies are summarized in Table 2 . Wide variability in CYP2A6, CYP2B6 and CYP2E1 deletion/duplication allele frequencies was observed across the tested populations ranging from 0 to 8.3% for deletions and 0 to 4.1% for duplications. The total CNV allele frequencies were 9.0% for African-Americans, 10.3% for Asians, 4.4% for Caucasians, 5.5% for Hispanics and 2.4% for the AJ (Table 2 ). All detected CYP2A6, CYP2B6 and CYP2E1 CNVs were validated by TaqMan qPCR copy number assays, indicating that the multiplexed MLPA assay was robust at detecting CYP450 CNVs. The genomic locations of MLPA and TaqMan probes are illustrated in Supplementary Figure S1 .
Breakpoint identification by aCGH The CYP2A6, CYP2B6 and CYP2E1 breakpoint intervals were further refined by aCGH using a custom high-density oligonucleotide microarray on a subset of 46 samples with CYP450 CNVs as determined by MLPA and qPCR (Table 3 ). The University of California Santa Cruz (UCSC) Genome Browser (http://genome. ucsc.edu/; human genome build GRCh37/hg19) was used to visualize the location of known human genes from the NCBI reference sequence collection (RefSeq), structural variants from the Database of Genomic Variants (DGV; http://projects.tcag.ca/ variation/), segmental duplications/low-copy repeats (LCRs) and low-complexity repetitive elements (for example, short interspersed elements (SINEs) and long interspersed elements (LINEs)).
CYP2A6
Both CYP2A6 deletion and duplication alleles were detected by MLPA with copy number probes in exons 1, 2 and 5. The deletion allele was detected in all populations except the AJ and was most common among Asians (8.3%). In contrast, the duplication allele frequency was highest among the AJ (2.0%) but not detected in the Caucasian or Hispanic populations. Two TaqMan qPCR assays (exons 1 and 7; Supplementary Figure S1 ) confirmed the MLPA results and indicated that the identified deletions and duplications likely encompassed the entire CYP2A6 gene (Figure 1 ). However, any CYP2A6/2A7 gene conversions in the 3 0 flanking region 35 would not be detected by these MLPA or qPCR assays. High-resolution aCGH mapped the mean size of the CYP2A6 deletion and duplication to B32 kb at 19q13.2 (B41. and localized the CNV breakpoints to a cluster of Alu and LINE elements within the 3 0 flanking regions of CYP2A6 and the more distal homologous CYP2A7 gene (Figure 1 ). The identified breakpoints mapped to two directly oriented LCRs: chr19:41 336 557-41 361 522 (proximal) and chr19:41 367 421-41 393 307 (distal) ( Table 3 ). Sequence alignment indicated that the two LCRs share 490% sequence homology and encompass both CYP2A6 and CYP2A7 (Figure 1 ).
CYP2B6
Identification of the CYP2B6/2B7P1 duplicated fusion allele (CYP2B6*30). Both CYP2B6 deletion and duplication alleles were detected in the African-American and Asian populations, respectively, by MLPA with copy number probes in exons 2, 3 and 4. Two TaqMan qPCR assays were used to confirm these results, one in exon 4 and a second located 12.6 kb downstream of the CYP2B6 gene (Supplementary Figure S1) . No commercial TaqMan probes were available that specifically interrogated exons 5-9 of CYP2B6. Interestingly, whereas the exon 4 TaqMan probe confirmed the MLPA results, the downstream TaqMan probe indicated a normal balanced copy number, suggesting the possibility of partial CYP2B6 deletion and duplication (Figure 2 ).
High-resolution aCGH mapped the size of the CYP2B6 deletion and duplication to B70 kb at 19q13.2 (B41.45-41.51 Mb) and localized the CNV breakpoints to a homologous region within intron 4 of both CYP2B6 and the proximal CYP2B7P1 pseudogene (Figure 2 ). The identified breakpoints mapped to two directly oriented LCRs: chr19:41 426 446-41 460 038 (proximal) and chr19:41 494 916-41 528 965 (distal) ( Table 3) . Sequence alignment indicated that the two LCRs share 490% sequence homology ( Figure 2 ). These results suggested that the partial deletion allele represented the previously reported CYP2B6*29 allele 36 and the partial duplication represented a reciprocal, and novel, CYP2B6/2B7P1 duplicated fusion allele (Figures 2 and 3) . The data for this allele, including the sequencing described below, were reviewed by the Cytochrome P450 Allele Nomenclature Committee 37, 38 and it subsequently has been designated as CYP2B6*30 (http://www.cypalleles.ki.se/cyp2b6.htm).
Sequence analyses of CYP2B6*29 and *30. A long-range PCRbased strategy was employed to interrogate the breakpoint regions of the identified CYP2B6*29 deletion and CYP2B6*30 Multi-ethnic CYP450 copy number variation S Martis et al duplication fusion alleles ( Figure 3 ). All breakpoint spanning amplicons were sequenced and the putative breakpoint regions were identified by multiple sequence alignment using CLUSTAL (http://www.ebi.ac.uk/clustalw). Based on the alignment data, the breakpoint region was localized to a 529-bp interval within introns 4 and exons 5 of both CYP2B6 and CYP2B7P1 where the sequences of the two genes are nearly identical. Breakpoint junctions for CYP2B6*29 and *30 were defined at the locations where the nucleotide sequence changed from CYP2B7P1 to CYP2B6 and from CYP2B6 to CYP2B7P1, respectively (Figure 3 ; Supplementary  Figures S2 and S3) . The homologous introns 4 of CYP2B6 and CYP2B7P1 also contain four directly oriented Alu elements (AluSc, AluSx, AluSx and AluSg/x).
In addition, all CYP2B6*29 and *30 exons and exon-intron junctions were sequenced. The two alleles were translated using ExPasy (http://web.expasy.org) and aligned with CYP2B6 to identify polypeptide sequence alterations. Despite the unique breakpoint region identified in our study, the coding sequence of our CYP2B6*29 allele was consistent with that previously reported 36 (http://www.cypalleles.ki.se/cyp2b6.htm), sharing complete sequence identity with exons 1-4 of CYP2B7P1 and exons 5-9 of CYP2B6. Conversely, CYP2B6*30 shared complete sequence identity with exons 1-4 of CYP2B6 and exons 6-9 of CYP2B7P1. Given the high sequence homology between exons 5 of CYP2B6 and CYP2B7P1, it is unclear which gene this exon is derived from for CYP2B6*30. Figure S1) . All qPCR copy number data were consistent with those obtained by MLPA and indicated full gene duplication (Figure 4) .
High-resolution aCGH mapped the mean size of the CYP2E1 duplication to B130 kb at 10q26.3 (B135.250-135.381 Mb) and localized the CNV breakpoints to two directly oriented LCRs: chr10:135 236 151-135 249 933 (proximal) and chr10:135 380 989-135 394 059 (distal) ( Table 3 ). Sequence alignment indicated that the two LCRs share 498% sequence homology and encompass the majority of the SPRN gene and its distal SPRNP1 pseudogene (Figure 4 ).
Sequence analyses of the CYP2E1*1Cx2 duplication. Although the size of the CYP2E1 duplication (B130 kb) prevented the design of a duplication allele-specific PCR, common CYP2E1 variants were interrogated by direct sequencing of all samples harboring a CYP2E1 duplication. No CYP2E1*2, *3, *4, *5, *6 or *7 variants were identified among the duplication carriers; however, two 5 0 promoter region repeat alleles were identified, *1C (6 repeats) and *1D (8 repeats). 39 For heterozygous *1C/*1D carriers (n ¼ 7; 30% of duplication carriers), the phase could not be determined so the duplicated allele for these cases would either be *1Cx2 or *1Dx2. However, for homozygous *1C/*1C subjects (n ¼ 16; 70% of duplication carriers), the duplicated allele must also be *1C. For these subjects, all nine CYP2E1 exons were sequenced and no additional coding region variants were identified. These data also have been reviewed by the Cytochrome P450 Allele Nomenclature Committee and the duplication allele has been designated as CYP2E1*1Cx2 (http://www.cypalleles.ki.se/cyp2e1.htm). Notably, no CYP2E1*1D homozygotes were detected among the CYP2E1 duplication subjects, suggesting that the CYP2E1*1Dx2 allele is either uncommon or non-existent in the tested populations.
DISCUSSION
The paucity of CNV data among the CYP450 genes, with the notable exception of CYP2D6, prompted our copy number survey of CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4 and CYP3A5 in the African-American, Asian, Caucasian, Hispanic and AJ populations. Of the 11 genes analyzed, CNVs were detected and confirmed in CYP2A6, CYP2B6 and CYP2E1, with multi-ethnic frequencies ranging from 0 to 8.3% for deletions and 0 to 4.1% for duplications. Interestingly, the discordant CYP450 deletion and duplication allele frequencies (for example, CYP2A6 deletion (8.3%) and duplication (1.5%) frequencies among Asians) suggest that selective pressures likely have acted on certain alleles. CYP2D6 CNVs were also detected in all studied populations; however, these data are being integrated with CYP2D6 genotyping data for an independent manuscript in preparation. In addition to identifying the CNV frequencies for this panel of CYP450 genes, high-resolution aCGH and sequencing analyses facilitated the identification of the novel CYP2B6*30 duplicated fusion allele and CYP2E1*1Cx2. Moreover, these data indicate that common CYP450 CNV formation is likely mediated by NAHR resulting in both full gene and gene-fusion copy number imbalances.
CYP2A6 is a hepatic CYP450 enzyme primarily involved in the metabolism of nicotine, cotinine and nitrosamine precarcinogens. 40 The CYP2A6 gene is highly polymorphic and variant alleles have been associated with interindividual variability in nicotine metabolism, smoking behavior and tobacco-related cancer risk. 41 We detected wide variability in the distribution of CYP2A6 deletion alleles across the five tested populations with the highest frequency observed among Asians (8.3%). The duplication allele was detected at low frequencies (o2%) among the AfricanAmericans, Asians and AJ, and was not detected in either the Caucasian or Hispanic cohorts. Although deletions are often under stronger purifying selection pressure than duplications to remove deleterious variants from the population, 42 the high CYP2A6 deletion frequency observed in our Asian population could be due to its previous association with lower cancer risks among Asians 43 and, therefore, may actually confer a protective effect. Moreover, it has been suggested that the CYP2A6 deletion is a relatively recent genetic event that likely occurred after the Caucasoid/Asian split B35 000 years ago. 44 Using high-resolution aCGH, we mapped the size of the CYP2A6 deletion and duplication to B32 kb, with breakpoints localizing to the 3 0 regions of CYP2A6 and the distal homologous CYP2A7 gene. Both CYP2A6 and CYP2A7 are encompassed by two directly oriented LCRs with 490% sequence homology and the identified breakpoints clustered to repetitive Alu and LINE elements. NAHR during meiosis can generate rearrangements as a consequence of recombination between regions of high sequence homology like LCRs and dispersed Alu repetitive elements. 45 For CYP2A6, the presence of two direct LCRs likely renders the region susceptible to rearrangements, leading to NAHR-mediated reciprocal full gene deletion and duplication. 22 As such, the different subtypes of the CYP2A6 deletion allele (CYP2A6*4A-H) previously reported in African populations 46 are likely the result of unique breakpoints mediated by different homologous Alu and/or other neighboring low-complexity repeats. Moreover, gene conversions of the CYP2A6 3 0 flanking region by CYP2A7, 35 which would not be detected by the methods employed in the current study, are also likely mediated by these low-complexity repeats.
CYP2B6 is involved in the metabolism of anticancer agents (for example, cyclophosphamide and ifosfamide), anesthetics (for example, ketamine and propofol), and antiretrovirals (for example, efavirenz and nevirapine). Commonly tested variant CYP2B6 alleles include p.K262R (*4), p.R487C (*5) and p.[Q172H þ K262R] (*6). 47 Notably, the CYP2B6*6, *18 and *26 decreased activity alleles have been shown to influence the pharmacokinetics of the nonnucleoside reverse transcriptase inhibitor efavirenz, 48 which may have utility for CYP2B6 genotype-guided dose adjustment. 49 However, little is known about CNVs at this locus other than the CYP2B6*29 partial deletion allele. 36 By MLPA screening and qPCR assays, we identified both CYP2B6 deletion and duplication alleles that were limited to exons 1-4 of the CYP2B6 gene. High-resolution aCGH mapped the size of the CYP2B6 deletion/duplication to B70 kb and localized the CNV breakpoints to introns 4/exons 5 of CYP2B6 and the proximal CYP2B7P1 pseudogene, both within LCRs that share 490% sequence homology. Similarly to CYP2A6, these LCRs likely mediate NAHR between CYP2B6 and CYP2B7P1, resulting in the previously reported CYP2B6*29 partial deletion allele and the reciprocal, and novel, CYP2B6/2B7P1 duplicated fusion allele (designated as CYP2B6*30 by the Cytochrome P450 Nomenclature Committee). The CYP2B6*29 and *30 breakpoints were further narrowed by breakpoint-spanning PCR and sequencing, which indicated that unequal crossing over most likely occurred at a 529-bp interval within introns 4 and exons 5 of CYP2B6 and CYP2B7P1 where the two genes are nearly identical. Additionally, both introns 4 contain four directly oriented homologous Alu elements (AluSc, AluSx, AluSx and AluSg/x) that may also facilitate NAHR at this locus.
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CYP2B6*30 is predicted to have 15 amino-acid changes, including the p.R487C alteration consistent with the *5 allele. 51, 52 More importantly, the exon 7 p.R378X non-sense alteration characteristic of the CYP2B6*28 allele is also encoded by *30, indicating that the translated *30 polypeptide would be truncated and lacking a heme binding site. 53 Taken together, these aminoacid alterations indicate that the duplicated CYP2B6*30 allele is most likely non-functional. Detecting CNV alleles like CYP2B6*29 and *30 has significant pharmacogenetic implications when interpreting the metabolizer phenotype. For example, if just assessing copy number of exons 1 through 4, *30 could be misclassified as CYP2B6*1 Â 2, which predicts an ultra-rapid metabolizer phenotype. Although the CYP2B6*29 (deletion) and *30 (duplication) alleles were rare in the tested populations (B1% in African-Americans and Asians, respectively), these variant alleles have been identified in other population studies as evidenced by entries in the DGV for this region.
CYP2E1 metabolizes clinically important drugs such as acetaminophen, isoniazid and tamoxifen, and is involved in the activation of several procarcinogens. Additionally, CYP2E1 is the major component of the microsomal ethanol oxidizing system and accounts for B10% of ethanol oxidation in the liver, indicating that this locus likely has an important role in alcoholism and related disorders. For example, some studies previously have associated variant CYP2E1 alleles (for example, *1D, *5B and *6) with alcoholism and cancer development in different ethno-racial groups. [54] [55] [56] [57] [58] Notably, although the DGV indicates that the 10q26.3 region is copy number variable, no CYP2E1 CNV alleles previously have been characterized by the Cytochrome P450 Nomenclature Committee (http://www.cypalleles.ki.se/cyp2e1.htm).
Although we detected the CYP2E1 duplication (designated as CYP2E1*1Cx2 by the Cytochrome P450 Nomenclature Committee) in all populations except Asians, no deletion alleles were identified in any of the studied racial or ethnic groups. High-resolution aCGH mapped the size of the CYP2E1 duplication to B130 kb and localized the CNV breakpoints to two highly homologous directly oriented LCRs that share 498% sequence homology and include SPRN and its distal SPRNP1 pseudogene. Of note, SPRN is a member of the prion protein family and variant SPRN alleles have recently been associated with Creutzfeldt-Jakob disease susceptibility. 59 Additionally, our aCGH data indicate that the CYP2E1 duplication region also includes the SYCE1 gene. SYCE1 is recruited to the synaptonemal complex during meiosis and, interestingly, microdeletions that encompass SYCE1 recently have been associated with premature ovarian failure. 60 Together, these data suggest that 10q26.3 CNVs may have additional clinical relevance beyond CYP2E1 pharmacogenetics and that adaptive selective pressures may partly explain why deletions in this region were not detected in any of our tested populations.
In conclusion, MLPA and TaqMan qPCR assays were used to determine the frequencies of deletion and duplication alleles for 11 CYP450 genes in a multi-ethnic healthy cohort. In addition to CYP2D6, CNVs were detected in CYP2A6, CYP2B6 and CYP2E1, and their frequencies varied among the studied populations. Of note, the discordant deletion and duplication allele frequencies for certain CYP450 CNV alleles (for example, CYP2A6 duplication and CYP2E1 deletion) suggest that selective pressures have likely acted on these alleles. The identified CYP2A6, CYP2B6 and CYP2E1 CNV alleles and their frequencies are strongly supported by the entries in the DGV (http://projects.tcag.ca/variation/) from other population studies. Importantly, our study also identified the novel CYP2B6/2B7P1 duplicated fusion allele (designated as CYP2B6*30) and the CYP2E1 duplication (designated as CYP2E1*1Cx2). Moreover, high-resolution aCGH and sequencing analyses localized breakpoints to directly oriented LCRs with 490-98% homology, which indicate that common CYP450 CNV formation is likely mediated by NAHR resulting in both full gene and gene-fusion copy number imbalances. Detection of these CNVs should be considered when interrogating these genes for pharmacogenetic drug selection and dosing.
